A Phase 3 Study to Evaluate the Safety and Tolerability of L606 in Subjects With PAH or PH-ILD

Study Summary

This Phase 3, 2-part, open-label, multicenter study aims to demonstrate the safety and tolerability of L606 in patients with PAH or PH-ILD. The study will determine the short-term and long-term safety and tolerability of L606 in this patient population.

Conditions

Pulmonary Arterial Hypertension Pulmonary Hypertension Due to Lung Diseases

Interventions / Drugs

L606 inhalation suspension

View on ClinicalTrials.gov ↗

Sponsor

LQDA

Liquidia Technologies

Pulmonary

D36/100

Study Details

Enrollment28 participants

Primary Completion—

Lead SponsorLiquidia Technologies, Inc.

Data Retrieved2026-04-11 04:20:00.960787+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.